Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer

Journal of Urology

Volumn 194, Issue 4, 2015, Pages 1120-1131

  Hayashi, Tetsutaro ^a,b   Seiler, Roland ^a   Oo, Htoo Zarni ^a   Jäger, Wolfgang ^a   Moskalev, Igor ^a   Awrey, Shannon ^a   Dejima, Takashi ^a   Todenhöfer, Tilman ^a   Li, Na ^a   Fazli, Ladan ^a   Matsubara, Akio ^c   Black, Peter C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HIROSHIMA UNIVERSITY   (Japan)

^c NONE

Author keywords

apoptosis; cytotoxins; ERBB2 protein; human; trastuzumab; urinary bladder neoplasms

Indexed keywords

AGAR; CISPLATIN; CYTOTOXIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL CULTURE; COLONY FORMATION; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAYTANSINE; MICE; RECEPTOR, ERBB-2; TRASTUZUMAB; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84941599612     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.05.087     Document Type: Article

References (30)

1. P. Black, and A. So Perioperative chemotherapy for muscle-invasive bladder cancer Can Urol Assoc J 3 suppl. 2009 S223
2. K.M. Gust, D.J. McConkey, S. Awrey, and et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer Mol Cancer Ther 12 2013 1245
3. G.D. Lewis Phillips, G. Li, D.L. Dugger, and et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 2008 9280
4. M. Barok, M. Tanner, K. Koninki, and et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer Cancer Lett 306 2011 171
5. M. Lae, J. Couturier, S. Oudard, and et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Ann Oncol 21 2010 815
6. A. Fleischmann, D. Rotzer, R. Seiler, and et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours Eur Urol 60 2011 350
7. M.H. Hussain, G.R. MacVicar, D.P. Petrylak, and et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J Clin Oncol 25 2007 2218
8. R.E. Jimenez, M. Hussain, F.J. Bianco Jr., and et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 7 2001 2440
9. C. Bolenz, S.F. Shariat, P.I. Karakiewicz, and et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder BJU Int 106 2010 1216
10. P.D. Grivas, M. Day, and M. Hussain Urothelial carcinomas: a focus on human epidermal receptors signaling Am J Transl Res 3 2011 362
11. F. Koga, S. Yoshida, M. Tatokoro, and et al. ErbB2 and NFkappaB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer PLoS One 6 2011 e27616
12. A. Chakravarti, K. Winter, C.L. Wu, and et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2005 309
13. C. Wulfing, J.P. Machiels, D.J. Richel, and et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 2009 2881
14. S. Oudard, S. Culine, Y. Vano, and et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 Eur J Cancer 51 2015 45
15. S. Verma, D. Miles, L. Gianni, and et al. Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783
16. A.C. Wolff, M.E. Hammond, D.G. Hicks, and et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997
17. D. Cretella, F. Saccani, F. Quaini, and et al. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance Mol Cancer 13 2014 143
18. W. Jager, I. Moskalev, C. Janssen, and et al. Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach PLoS One 8 2013 e59536
19. Y. Chekaluk, C.L. Wu, J. Rosenberg, and et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value PLoS One 8 2013 e60927
20. J. Diessner, V. Bruttel, R.G. Stein, and et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) Cell Death Dis 5 2014 e1149
21. M. Rink, F.K. Chun, R. Dahlem, and et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study Eur Urol 61 2012 810
22. M. Barok, J. Isola, Z. Palyi-Krekk, and et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance Mol Cancer Ther 6 2007 2065
23. M. Barok, M. Tanner, K. Koninki, and et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo Breast Cancer Res 13 2011 R46
24. T.T. Junttila, G. Li, K. Parsons, and et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res Treat 128 2011 347
25. P.M. LoRusso, D. Weiss, E. Guardino, and et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin Cancer Res 17 2011 6437
26. S. Girish, M. Gupta, B. Wang, and et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother Pharmacol 69 2012 1229
27. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315
28. S. Ithimakin, K.C. Day, F. Malik, and et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Res 73 2013 1635
29. J.S. Damrauer, K.A. Hoadley, D.D. Chism, and et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc Natl Acad Sci U S A 111 2014 3110
30. A. Dash, M.D. Galsky, A.J. Vickers, and et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506